US 8044201B2
· Xu et al.
· 2011
[cited by applicant]
US 9233125B2
· Davila et al.
· 2016
[cited by applicant]
US 9376664B2
· Efe et al.
· 2016
[cited by applicant]
US 9556417B2
· Efe et al.
· 2017
[cited by applicant]
US 9828399B2
· Tremblay et al.
· 2017
[cited by applicant]
US 20010053361A1
· Thompson et al.
· 2001
[cited by applicant]
US 20040175373A1
· Berenson et al.
· 2004
[cited by applicant]
US 20050075276A1
· Rudd
· 2005
[cited by applicant]
US 20060247214A1
· DeLong et al.
· 2006
[cited by applicant]
US 20180072992A1
· Valamehr et al.
· 2018
[cited by applicant]
CN 102027105A
· 2011
[cited by applicant]
EP 2303319A2
· 2011
[cited by applicant]
EP 2638896A1
· 2012
[cited by applicant]
GB 2444853A
· 2008
[cited by applicant]
GB 2444853B
· 2008
[cited by applicant]
JP 2019502725A
· 2019
[cited by applicant]
WO WO9901426A1
· 1999
[cited by applicant]
WO WO0112596A1
· 2001
[cited by applicant]
WO WO0206213A2
· 2002
[cited by applicant]
WO WO0206213A3
· 2002
[cited by applicant]
WO WO03077914A1
· 2003
[cited by applicant]
WO WO2005051301A2
· 2005
[cited by applicant]
WO WO2005051301A3
· 2005
[cited by applicant]
WO WO2007044084A2
· 2007
[cited by applicant]
WO WO2007044084A3
· 2007
[cited by applicant]
WO WO2007103901A2
· 2007
[cited by applicant]
WO WO2007103901A3
· 2007
[cited by applicant]
WO WO2008006583A1
· 2008
[cited by applicant]
WO WO2009117439A2
· 2009
[cited by applicant]
WO WO2009155535A2
· 2009
[cited by applicant]
WO WO2010083298A1
· 2010
[cited by applicant]
WO WO2015155738A2
· 2015
[cited by applicant]
WO WO2015155738A3
· 2015
[cited by applicant]
WO WO2015160986A2
· 2015
[cited by applicant]
WO WO2015160986A3
· 2015
[cited by applicant]
WO WO2015188119
· 2015
[cited by examiner]
WO WO2015188119A1
· 2015
[cited by applicant]
WO WO2016040892A1
· 2016
[cited by applicant]
WO WO2016123100A1
· 2016
[cited by applicant]
WO WO2016123117A1
· 2016
[cited by applicant]
WO WO2016160621A2
· 2016
[cited by applicant]
WO WO2016160621A3
· 2016
[cited by applicant]
WO WO2016179283A1
· 2016
[cited by applicant]
WO WO2016187158A1
· 2016
[cited by applicant]
WO WO2017078807A1
· 2017
[cited by applicant]
WO WO2017078807A9
· 2017
[cited by applicant]
WO WO2017127729A1
· 2017
[cited by applicant]
WO WO2017127755A1
· 2017
[cited by applicant]
WO WO2018231951A1
· 2018
[cited by applicant]
Nikiforow 2013 Biol Blood Marow Transplant Abstract 187 (Year: 2013).
[cited by examiner]
Wu 2014 Transplantation Abstract D2799 (Year: 2014).
[cited by examiner]
Aoukaty, A. et al. (Apr. 15, 2005). “Role for glycogen synthase kinase-3 in NK cell cytotoxicity and X-linked lymphoproliferative disease,”
[cited by applicant]
Araki, K. et al. (Jul. 2, 2009, e-published Jun. 21, 2009). “mTOR regulates memory CD8 T-cell differentiation,”
[cited by applicant]
Araki, K. et al. (May 2010). “The role of mTOR in memory CD8 T-cell differentiation,”
[cited by applicant]
Asanuma, S. et al. (Jun. 2011, e-published Nov. 24, 2010). “Expansion of CD4(+)CD25 (+) regulatory T cells from cord blood CD4(+) cells using the common γ-chain cytokines (IL-2 and IL-15) and rapamycin,”
[cited by applicant]
Battaglia, M. et al. (Jun. 15, 2005, e-published Mar. 3, 2005). “Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells,”
[cited by applicant]
Berger, C. et al (Jan. 2008). “Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates,”
[cited by applicant]
Cao et al., “Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells,”
[cited by applicant]
Chang, C.H. et al. (Jun. 6, 2013). “Posttranscriptional control of T cell effector function by aerobic glycolysis,”
[cited by applicant]
Cheng, M. et al. (May 2013, e-published Apr. 22, 2013). “NK cell-based immunotherapy for malignant diseases,”
[cited by applicant]
Esteban, M.A. et al. (Jan. 8, 2010, e-published Dec. 31, 2009). “Vitamin C enhances the generation of mouse and human induced pluripotent stem cells,”
[cited by applicant]
Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase lb Study of Prohema(R) (Feb. 26, 2014). located at <http://ir.fatetherapeutics.com/releasedetail.cfm?releasei…
[cited by applicant]
Feng, B. et al. (Apr. 3, 2009). “Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells,”
[cited by applicant]
Goessling, W. et al. (Apr. 8, 2011). “Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models,”
[cited by applicant]
Goldman et al., “Immunology Overview,”
[cited by applicant]
Huangfu, D et al. (Jul. 2008, e-published Jun. 22, 2008). “Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds,”
[cited by applicant]
Huangfu, D et al. (Nov. 2008, e-published Oct. 12, 2008). “Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2,”
[cited by applicant]
Ichida, J.K. et al. (Nov. 6, 2009, e-published Oct. 8, 2009). “A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog,”
[cited by applicant]
Inman, G.J. et al. (Jul. 2002). “SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7,”
[cited by applicant]
Kim, D. et al. (Jun. 5, 2009, e-published May 28, 2009). “Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins,”
[cited by applicant]
Kim, G.G. et al. (Aug. 31, 2007, e-published Jun. 28, 2007). “A novel multiparametric flow cytometry-based cytotoxicity assay simultaneously immunophenotypes effector cells: comparisons to a 4 h 51Cr-release assay,”
[cited by applicant]
King, C.C. et al. (Jun. 16, 2000). “Sphingosine is a novel activator of 3-phosphoinositide-dependent kinase 1,”
[cited by applicant]
Liu, Y. et al. (Jan. 2015, e-published Jul. 14, 2014). “mTOR signaling in T cell immunity and autoimmunity,”
[cited by applicant]
Lyssiotis, C.A. et al. (Jun. 2, 2009, e-published May 15, 2009). “Reprogramming of murine fibroblasts to induced pluripotent stem cells with chemical complementation of Klf4,” PNAS USA 106(22):8912-8917.
[cited by applicant]
Mack et al., “Generation of induced pluripotent stem cells from CD34+ cells across blood drawn from multiple donors with non-integrating episomal vectors,”
[cited by applicant]
Maherali, N. et al. (Nov. 3, 2009, e-published Sep. 17, 2009). “Tgfβ signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc,”
[cited by applicant]
Nerreter et al., “Combining dasatinib with dexamethasone long-term leads to maintenance of antiviral and antileukemia specific cytotoxic T cell responses in vitro,”
[cited by applicant]
Nikiforow et al., “Evolution of T Cell Repertoire Diversity After Reduced-Intensity Conditioning and Double Umbilical Cord Blood Transplantation with or without Exposure to FT1050 (16, 16-dimethyl Prostaglandin E2)”
[cited by applicant]
Parameswaran et al., “Repression of GSK3 restores NK cell cytotoxicity in AML patients,”
[cited by applicant]
Perkins, M.R. et al. (Dec. 3, 2015). “Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells,”
[cited by applicant]
Robson et al., “Optimal effector functions in human natural killer cells rely upon autocrine bone morphogenetic protein signaling,”
[cited by applicant]
Rosen, J. et al. (Dec. 2, 2016). “Identification of small molecule modulators to enhance the therapeutic properties of chimeric antigen receptor T cells,”
[cited by applicant]
Roskoski et al., “Properties of FDA-approved small molecule protein kinase inhibitors,”
[cited by applicant]
Rossari et al., “Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy,”
[cited by applicant]
Rutishauser, R.L. et al. (Aug. 21, 2009, e-published Aug. 6, 2009). “Transcriptional repressor Blimp-1 promotes CD8(+) T cell terminal differentiation and represses the acquisition of central memory T cell properties,”
[cited by applicant]
Saha, K. et al. (Dec. 4, 2009). “Technical challenges in using human induced pluripotent stem cells to model disease,”
[cited by applicant]
Schwarzbich et al., “The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR-ABL tyrosine kinase inhibitors,”
[cited by applicant]
Shi, Y. et al. (Jun. 5, 2008). “A combined chemical and genetic approach for the generation of induced pluripotent stem cells,”
[cited by applicant]
Shi, Y. et al. (Nov. 6, 2008). “Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds,”
[cited by applicant]
Silva, J. et al. (Oct. 21, 2008). “Promotion of reprogramming to ground state pluripotency by signal inhibition,”
[cited by applicant]
Sommermeyer, D. et al. (Feb. 2016, e-published Sep. 15, 2015). “Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo,”
[cited by applicant]
Sukumar, M. et al. (Oct. 2013, Sep. 16, 2013). “Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function,”
[cited by applicant]
Takahashi, K. et al. (Aug. 25, 2006, e-published Aug. 10, 2006). “Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors,”
[cited by applicant]
Takahashi, K. et al. (Nov. 30, 2007). “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,”
[cited by applicant]
Wai, L-E. et al. (Jan. 15, 2008). “Rapamycin, but not cyclosporine or FK506, alters natural killer cell function,”
[cited by applicant]
Wolleschak et al., “FLT3-Kinase Inhibitors Quizartinib and Midostaurin Do Not Impair T-Cell Reactivity and Activation,”
[cited by applicant]
Wu et al., “Rapamycin Promotes Expansion of CD4+CD25+FOXP3+Regulatory T Cells by Modulating Fatty Acid Metabolism,”
[cited by applicant]
Yamanaka, S. et al. (Jul. 2, 2009). “Elite and stochastic models for induced pluripotent stem cell generation,”
[cited by applicant]
Yu, J. et al. (Dec. 21, 2007, e-published Nov. 20, 2007). “Induced pluripotent stem cell lines derived from human somatic cells,”
[cited by applicant]
Zhang, J.Y. et al. (Jan. 10, 2018). “Modulation of CD8 + memory stem T cell activity and glycogen synthase kinase 3β inhibition enhances anti-tumoral immunity in gastric cancer,”
[cited by applicant]
Zhou, H. et al. (May 8, 2009, e-published Apr. 23, 2009). “Generation of induced pluripotent stem cells using recombinant proteins,”
[cited by applicant]
Zhou, X. et al. (Sep. 15, 2012, e-published Aug. 8, 2012). “Cutting edge: generation of memory precursors and functional memory CD8+ T cells depends on T cell factor-1 and lymphoid enhancer-binding factor-1,”
[cited by applicant]
Baker et al., “Prostaglandin inhibition of T-cell proliferation is mediated at two levels,”
[cited by applicant]
Barbey et al., “Ex vivo monitoring of antigen-specific CD4+ T cells after recall immunization with tetanus toxoid,”
[cited by applicant]
Chan et al., “Conformational Control Inhibition of the BCR-ABL 1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036,”
[cited by applicant]
Garcillán et al., “γδ T lymphocytes in the diagnosis of human t cell receptor immunodeficiencies,”
[cited by applicant]
Kalinski, “Regulation of immune responses by prostaglandin E2,”
[cited by applicant]
Parameswaran et al., “Novel Approach for NK Cell Therapy for Cancer,”
[cited by applicant]
Sakata et al., “Prostaglandin E2, an immunoactivator,”
[cited by applicant]
Seggewiss et al., “Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner,”
[cited by applicant]
Tighe et al., “GSK-3 inhibitors induce chromosome instability,”
[cited by applicant]
Weichsel et al., “Profound Inhibition of Antigen-SpecificT-Cell Effector Functions by Dasatinib.,”
[cited by applicant]
Yoshioka et al., “Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation,”
[cited by applicant]
Blazar et al., U.S. Appl. No. 62/264,455, filed Dec. 8, 2015.
[cited by applicant]
Campbell et al., “CCR7 expression and memory T cell diversity in humans,”
[cited by applicant]
Fujisaki, H. et al. (May 1, 2009, e-published Apr. 21, 2009). “Expansion of highly cytotoxic human natural killer cells for cancer cell therapy,”
[cited by applicant]
Mestermann et al., “The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CART cells,”
[cited by applicant]
Mustjoki et al., “Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy,”
[cited by applicant]
Soriani et al., “Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma,”
[cited by applicant]
Wu et al., “Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment,”
[cited by applicant]